China-based Innovent Biologics, Inc. and Eli Lilly and Co. ( LLY ) announced Friday that their co-developed Tyvyt, a fully human anti-PD-1 therapeutic monoclonal antibody, has been granted approval for market authorization by the National Medical Products Administration or NMPA of China.
https://www.nasdaq.com/article/innovent-lilly-codeveloped-tyvyt-gets-chinas-nmpa-approval-for-chl-20181227-00038
Innovent, Lilly Co-developed Tyvyt Gets China’s NMPA Approval For CHL